Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" Rating

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) was upgraded by equities research analysts at Wall Street Zen to a "hold" rating in a research report issued on Friday.

Separately, HC Wainwright restated a "neutral" rating and issued a $20.00 price objective on shares of Lyell Immunopharma in a research report on Wednesday, April 16th.

Lyell Immunopharma Trading Up 11.3%

Lyell Immunopharma stock traded up $1.30 during midday trading on Friday, hitting $12.76. The stock had a trading volume of 383,052 shares, compared to its average volume of 64,703. Lyell Immunopharma has a 52-week low of $7.65 and a 52-week high of $53.50. The company has a market capitalization of $188.95 million, a PE ratio of -16.15 and a beta of -0.26. The firm's fifty day moving average is $8.88 and its two-hundred day moving average is $11.97.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The company reported ($3.60) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.80) by $0.20. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. The firm had revenue of $0.01 million during the quarter. As a group, equities research analysts predict that Lyell Immunopharma will post -0.78 earnings per share for the current fiscal year.

Insider Activity at Lyell Immunopharma

In other Lyell Immunopharma news, CFO Charles W. Newton purchased 10,000 shares of Lyell Immunopharma stock in a transaction that occurred on Monday, March 17th. The shares were bought at an average price of $11.20 per share, for a total transaction of $112,000.00. Following the completion of the transaction, the chief financial officer now owns 10,000 shares of the company's stock, valued at approximately $112,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Lynn Seely purchased 8,750 shares of the firm's stock in a transaction that occurred on Friday, March 14th. The shares were acquired at an average cost of $12.20 per share, for a total transaction of $106,750.00. Following the purchase, the chief executive officer now owns 35,625 shares of the company's stock, valued at $434,625. This represents a 32.56% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders purchased 38,432 shares of company stock valued at $449,508. Corporate insiders own 25.10% of the company's stock.

Hedge Funds Weigh In On Lyell Immunopharma

Several institutional investors have recently bought and sold shares of LYEL. SG Americas Securities LLC raised its position in shares of Lyell Immunopharma by 102.8% during the 4th quarter. SG Americas Securities LLC now owns 116,748 shares of the company's stock valued at $75,000 after buying an additional 59,182 shares in the last quarter. Charles Schwab Investment Management Inc. increased its stake in Lyell Immunopharma by 43.4% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,645,787 shares of the company's stock worth $1,053,000 after acquiring an additional 498,417 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Lyell Immunopharma by 347.8% during the fourth quarter. JPMorgan Chase & Co. now owns 433,265 shares of the company's stock worth $277,000 after acquiring an additional 336,516 shares during the last quarter. Takeda Pharmaceutical Co. Ltd. purchased a new stake in Lyell Immunopharma during the fourth quarter valued at approximately $527,000. Finally, Geode Capital Management LLC lifted its stake in shares of Lyell Immunopharma by 2.9% in the 4th quarter. Geode Capital Management LLC now owns 4,137,264 shares of the company's stock valued at $2,648,000 after purchasing an additional 117,303 shares during the last quarter. Institutional investors own 66.05% of the company's stock.

About Lyell Immunopharma

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.